Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28031637 | 0.93 | SMN1; SMN2 (0.51) | SMN1; SMN2GAAL3MBTL1EGFRLMNA | |
| SCHEMBL28724963 | 0.89 | SMN1; SMN2 (0.51) | SMN1; SMN2GAAL3MBTL1EGFRLMNA | |
| SCHEMBL22807323 | 0.88 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL838467 | 0.88 | SMN1; SMN2 (0.74) | SMN1; SMN2LMNAKDM4ETSHRMEN1 | |
| SCHEMBL31446775 | 0.88 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL23270679 | 0.88 | SMN1; SMN2 (0.50) | SMN1; SMN2GAAEGFRLMNAKDM4E | |
| SCHEMBL15777690 | 0.87 | SMN1; SMN2 (0.52) | SMN1; SMN2LMNAKDM4EMEN1KMT2A | |
| SCHEMBL8914214 | 0.85 | SMN1; SMN2 (0.51) | SMN1; SMN2GAAL3MBTL1LMNAKDM4E | |
| SCHEMBL31446049 | 0.84 | SMN1; SMN2 (0.47) | SMN1; SMN2GAAL3MBTL1EGFRLMNA | |
| SCHEMBL29907828 | 0.84 | SMN1; SMN2 (0.47) | SMN1; SMN2GAAL3MBTL1EGFRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117164593-A | Pyrimidoindoles compound, preparation method and application thereof, and anti-erythroleukemia drug | 贵州省天然产物研究中心 | 2023-12-05 | — | — | CN | claimed |
| US-12630554-B2 | Pyrimidinone compounds and uses thereof | HUTCHISON MEDIPHARMA LIMITED (CN) | 2026-05-19 | — | — | US | disclosed |
| CN-118339153-A | Heteroaromatic compounds for the treatment of cancer | 勃林格殷格翰国际有限公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20240002388-A1 | PYRIMIDINONE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2024-01-04 | — | — | US | disclosed |
| CN-117164593-A | Pyrimidoindoles compound, preparation method and application thereof, and anti-erythroleukemia drug | 贵州省天然产物研究中心 | 2023-12-05 | — | — | CN | disclosed |
| WO-2023117681-A1 | HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-06-29 | — | — | WO | disclosed |
| CN-116249696-A | Pyrimidinone compounds and use thereof | 和记黄埔医药（上海）有限公司 | 2023-06-09 | — | — | CN | disclosed |
| WO-2022037585-A1 | PYRIMIDINONE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2022-02-24 | — | — | WO | disclosed |
| WO-2022016642-A1 | CULTURE MEDIUM FOR LUNG CANCER EPITHELIAL CELL, CULTURE METHOD AND USE THEREOF | 合肥中科普瑞昇生物医药科技有限公司 | 2022-01-27 | — | — | WO | disclosed |
| EP-2584903-B1 | NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2018-10-24 | — | — | EP | disclosed |
| US-8999957-B2 | Heterocyclic compounds as ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-04-07 | — | — | US | disclosed |
| US-8999957-B2 | Heterocyclic compounds as ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-04-07 | — | — | US | disclosed |
| US-8999957-B2 | Heterocyclic compounds as ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-04-07 | — | — | US | disclosed |
| EP-2584903-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-05-01 | — | — | EP | disclosed |
| US-20130096084-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHBITORS | MERCK SHARP & DOHME LLC | 2013-04-18 | — | — | US | disclosed |
| US-20130096084-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHBITORS | MERCK SHARP & DOHME LLC | 2013-04-18 | — | — | US | disclosed |
| US-20130096084-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHBITORS | MERCK SHARP & DOHME LLC | 2013-04-18 | — | — | US | disclosed |
| WO-2011163330-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-12-29 | — | — | WO | disclosed |
| CN-101525339-A | Novel oxabispidine compounds and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB | 2009-09-09 | — | — | CN | disclosed |
| CN-1968956-A | Novel oxabispidine compounds and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2007-05-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096084-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHBITORS | MAPK1, MAPK6, MAPK3 | SMN1; SMN2 4688/4885GAA 3289/4885L3MBTL1 4072/4885 |
| US-20240002388-A1 | PYRIMIDINONE COMPOUNDS AND USES THEREOF | TYMP, DPYD, DHFR | SMN1; SMN2 1318/4885GAA 503/4885L3MBTL1 4634/4885 |
| US-12630554-B2 | Pyrimidinone compounds and uses thereof | CYP2D6, TPMT, CYP2B6 | SMN1; SMN2 1364/4885GAA 2937/4885L3MBTL1 4086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.